Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1996 May;70(5):3093–3097. doi: 10.1128/jvi.70.5.3093-3097.1996

A short peptide eluted from the H-2Kb molecule of a polyomavirus-positive tumor corresponds to polyomavirus large T antigen peptide at amino acids 578 to 585 and induces polyomavirus-specific immunity.

Z Berke 1, S Palmer 1, T Bergman 1, D Wester 1, J Svedmyr 1, S Linder 1, H Jornvall 1, T Dalianis 1
PMCID: PMC190171  PMID: 8627788

Abstract

A short peptide in complex with the H-2Kb molecule on PyRMA, a polyomavirus transfectant of the mouse lymphoma cell line RMA, was identified as a polyomavirus tumor-specific transplantation antigen. The peptide was obtained by affinity chromatography, acidic extraction, and reverse-phase high-pressure liquid chromatography (HPLC). In one HPLC fraction, a peptide sequence in which 5 of 8 amino acids, GKxGLxxA, corresponded to residues 578 to 585 of polyomavirus large T antigen was identified. In tumor rejection assays, we therefore tested three related synthetic peptides, corresponding to the octapeptide LT 578-585, GKTGLAAA; the nonapeptide LT 578-586, GKTGLAAAL; and the decapeptide LT 578-587, GKTGLAAALI. The octapeptide was found to give the most effective immunization against the outgrowth of the polyomavirus DNA-positive PyRMA tumor. However, none of the three peptides immunized against the original polyoma-virus-negative RMA line.

Full Text

The Full Text of this article is available as a PDF (237.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aichele P., Hengartner H., Zinkernagel R. M., Schulz M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J Exp Med. 1990 May 1;171(5):1815–1820. doi: 10.1084/jem.171.5.1815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bergman T., Jörnvall H. Electroblotting of individual polypeptides from SDS/polyacrylamide gels for direct sequence analysis. Eur J Biochem. 1987 Nov 16;169(1):9–12. doi: 10.1111/j.1432-1033.1987.tb13573.x. [DOI] [PubMed] [Google Scholar]
  3. Berke Z., Dalianis T. Persistence of polyomavirus in mice infected as adults differs from that observed in mice infected as newborns. J Virol. 1993 Jul;67(7):4369–4371. doi: 10.1128/jvi.67.7.4369-4371.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Berke Z., Wen T., Jin S., Klein G., Dalianis T. Polyomavirus persists in CD4/8 double-knockout, but not in CD4 or CD8 single-knockout mice. Virology. 1995 Sep 10;212(1):268–271. doi: 10.1006/viro.1995.1482. [DOI] [PubMed] [Google Scholar]
  5. Bright R. K., Shearer M. H., Kennedy R. C. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity. J Immunol. 1994 Sep 1;153(5):2064–2071. [PubMed] [Google Scholar]
  6. Dalianis T., Magnusson G., Ito Y., Klein G. Immunization against the polyoma virus-induced tumor-specific transplantation antigen by early region mutants of the virus. J Virol. 1982 Sep;43(3):772–777. doi: 10.1128/jvi.43.3.772-777.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dalianis T., Ramqvist T., Klein G. Studies on the polyoma-virus-induced tumor-specific transplantation antigen (TSTA)--does middle or large T-antigen play a role? Int J Cancer. 1984 Sep 15;34(3):403–406. doi: 10.1002/ijc.2910340318. [DOI] [PubMed] [Google Scholar]
  8. Dalianis T. Studies on the polyoma virus tumor-specific transplantation antigen (TSTA). Adv Cancer Res. 1990;55:57–85. doi: 10.1016/s0065-230x(08)60468-6. [DOI] [PubMed] [Google Scholar]
  9. Engelhard V. H. Structure of peptides associated with MHC class I molecules. Curr Opin Immunol. 1994 Feb;6(1):13–23. doi: 10.1016/0952-7915(94)90028-0. [DOI] [PubMed] [Google Scholar]
  10. Falk K., Rötzschke O., Stevanović S., Jung G., Rammensee H. G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991 May 23;351(6324):290–296. doi: 10.1038/351290a0. [DOI] [PubMed] [Google Scholar]
  11. Feltkamp M. C., Smits H. L., Vierboom M. P., Minnaar R. P., de Jongh B. M., Drijfhout J. W., ter Schegget J., Melief C. J., Kast W. M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993 Sep;23(9):2242–2249. doi: 10.1002/eji.1830230929. [DOI] [PubMed] [Google Scholar]
  12. Fried M., Griffin B. E., Lund E., Robberson D. L. Polyoma virus--a study of wild-type, mutant and defective DNAs. Cold Spring Harb Symp Quant Biol. 1975;39(Pt 1):45–52. doi: 10.1101/sqb.1974.039.01.009. [DOI] [PubMed] [Google Scholar]
  13. Greene M. I., Perry L. L., Kinney-Thomas E., Benjamin T. L. Specific thymus-derived (T) cell recognition of papova virus-transformed cells. J Immunol. 1982 Feb;128(2):732–736. [PubMed] [Google Scholar]
  14. Joyce S., Nathenson S. G. Methods to study peptides associated with MHC class I molecules. Curr Opin Immunol. 1994 Feb;6(1):24–31. doi: 10.1016/0952-7915(94)90029-9. [DOI] [PubMed] [Google Scholar]
  15. Liunggren G., Liunggren H. G., Dalianis T. T cell subsets involved in immunity against polyoma virus-induced tumors. Virology. 1994 Feb;198(2):714–716. doi: 10.1006/viro.1994.1084. [DOI] [PubMed] [Google Scholar]
  16. Ljunggren H. G., Kärre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med. 1985 Dec 1;162(6):1745–1759. doi: 10.1084/jem.162.6.1745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lukacher A. E., Ma Y., Carroll J. P., Abromson-Leeman S. R., Laning J. C., Dorf M. E., Benjamin T. L. Susceptibility to tumors induced by polyoma virus is conferred by an endogenous mouse mammary tumor virus superantigen. J Exp Med. 1995 May 1;181(5):1683–1692. doi: 10.1084/jem.181.5.1683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Luthman H., Nilsson M. G., Magnusson G. Non-contiguous segments of the polyoma genome required in cis for DNA replication. J Mol Biol. 1982 Nov 15;161(4):533–550. doi: 10.1016/0022-2836(82)90406-5. [DOI] [PubMed] [Google Scholar]
  19. MILLER J. F. INFLUENCE OF THYMECTOMY ON TUMOR INDUCTION BY POLYOMA VIRUS IN C57BL MICE. Proc Soc Exp Biol Med. 1964 Jun;116:323–327. doi: 10.3181/00379727-116-29237. [DOI] [PubMed] [Google Scholar]
  20. Ramqvist T., Pallas D. O., DeAnda J., Ahrlund-Richter L., Reinholdsson G., Roberts T. M., Schaffhausen B. S., Dalianis T. Immunization against the polyoma tumor-specific transplantation antigen (TSTA) with polyoma T-antigens. Int J Cancer. 1988 Jul 15;42(1):123–128. doi: 10.1002/ijc.2910420123. [DOI] [PubMed] [Google Scholar]
  21. Ramqvist T., Reinholdsson G., Carlquist M., Bergman T., Dalianis T. A single peptide derived from the sequence common to polyoma small and middle T-antigen induces immunity against polyoma tumors. Virology. 1989 Sep;172(1):359–362. doi: 10.1016/0042-6822(89)90140-2. [DOI] [PubMed] [Google Scholar]
  22. Reddehase M. J., Rothbard J. B., Koszinowski U. H. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature. 1989 Feb 16;337(6208):651–653. doi: 10.1038/337651a0. [DOI] [PubMed] [Google Scholar]
  23. Reinholdsson-Ljunggren G., Ramqvist T., Ahrlund-Richter L., Dalianis T. Immunization against polyoma tumors with synthetic peptides derived from the sequences of middle- and large-T antigens. Int J Cancer. 1992 Jan 2;50(1):142–146. doi: 10.1002/ijc.2910500128. [DOI] [PubMed] [Google Scholar]
  24. Rötzschke O., Falk K., Deres K., Schild H., Norda M., Metzger J., Jung G., Rammensee H. G. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature. 1990 Nov 15;348(6298):252–254. doi: 10.1038/348252a0. [DOI] [PubMed] [Google Scholar]
  25. SJOEGREN H. O. STUDIES ON SPECIFIC TRANSPLANTATION RESISTANCE TO POLYOMA-VIRUS-INDUCED TUMORS. I. TRANSPLANTATION RESISTANCE INDUCED BY POLYOMA VIRUS INFECTION. J Natl Cancer Inst. 1964 Feb;32:361–374. [PubMed] [Google Scholar]
  26. Soeda E., Arrand J. R., Smolar N., Walsh J. E., Griffin B. E. Coding potential and regulatory signals of the polyoma virus genome. Nature. 1980 Jan 31;283(5746):445–453. doi: 10.1038/283445a0. [DOI] [PubMed] [Google Scholar]
  27. Townsend A. R., Rothbard J., Gotch F. M., Bahadur G., Wraith D., McMichael A. J. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 1986 Mar 28;44(6):959–968. doi: 10.1016/0092-8674(86)90019-x. [DOI] [PubMed] [Google Scholar]
  28. Van Bleek G. M., Nathenson S. G. Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature. 1990 Nov 15;348(6298):213–216. doi: 10.1038/348213a0. [DOI] [PubMed] [Google Scholar]
  29. Vandeputte M. The effect of heterologous antilymphocytic serum on the oncogenic activity of polyoma virus. Life Sci. 1968 Aug 15;7(16):855–865. doi: 10.1016/0024-3205(68)90117-3. [DOI] [PubMed] [Google Scholar]
  30. Zhou X., Berg L., Motal U. M., Jondal M. In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides. J Immunol Methods. 1992 Aug 30;153(1-2):193–200. doi: 10.1016/0022-1759(92)90322-k. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES